Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2009-10-05 Regulatory Filings
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Successful HCV Trial Results 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release dated 6 October 2009 from Biotron Limited announcing the successful completion of a Phase Ib/IIa clinical trial for their drug BIT225 targeting Hepatitis C virus (HCV). It details trial results, safety, tolerability, and preliminary efficacy data. The document is about clinical trial results and drug development progress, not a financial report, regulatory filing, or shareholder meeting material. It does not contain financial statements, management discussion of financial results, or regulatory certifications. It is an announcement of clinical trial results, which fits best under the category of a general regulatory announcement or compliance document related to company operations and progress. Given the absence of any other more specific category, the best fit is Regulatory Filings (RNS). The document length is about 6000 characters, which is not extremely short, but the content is clearly an announcement rather than a full report or presentation.
2009-10-05 English
Annual Report and Notice of AGM 45 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2009' and references the company's Annual Report for the year ended 30 June 2009. It includes detailed sections such as operating and financial review, corporate governance, directors' report, income statement, balance sheet, cash flow statement, notes to financial statements, directors' declaration, and independent audit report. The content covers comprehensive financial performance, business developments, clinical trial progress, capital raising, and outlook, consistent with a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or notice. Therefore, this document fits the definition of an Annual Report (10-K). FY 2009
2009-09-28 English
Preliminary Final Report 45 pages ?Kb
Annual Report Classification · 100% confidence The document is a detailed communication from Biotron Limited dated 28 August 2009, including a Preliminary Final Report (Appendix 4E) and the Annual Report for the year ended 30 June 2009. It contains extensive financial data, operating and financial review, clinical development updates, patent portfolio details, and capital raising information. The document explicitly states it includes the Annual Report and audited year-end accounts. The length (15,000 characters) and content indicate this is the full Annual Report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K) filing, which covers the company's yearly activity and full financial performance. FY 2009
2009-08-27 English
Completion of Clinical Stage of HCV Trial 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement (2 pages, 4298 characters) from Biotron Limited dated 4 August 2009, addressed to the ASX Limited. It announces the completion of the clinical or treatment stage of a Phase Ib/IIa clinical trial for a drug targeting Hepatitis C virus (HCV). The content focuses on the milestone completion of a clinical trial phase, describing the study design, objectives, and next steps for data review. There are no financial statements, detailed financial performance data, or regulatory filings related to financial results. The document is not a full report but an update on a clinical trial milestone, which is typical of a regulatory announcement or general company update to the market. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a call transcript or AGM material. It is an announcement of a significant operational milestone relevant to investors and the market. Given the short length and nature of the content, it aligns best with Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2009-08-03 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including consolidated cash flow statements, payments to directors, financing facilities, reconciliation of cash, and compliance statements. The presence of quarterly financial data and the nature of the report align with an Interim / Quarterly Report. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an Annual Report, Earnings Release, or other types of filings. The Appendix 4C is a recognized form for quarterly cash flow reporting in Australian markets, consistent with an Interim / Quarterly Report (IR). Q4 2009
2009-07-23 English
Response to ASX Query - Director`s Interest Notice 3 pages ?Kb
Director's Dealing Classification · 95% confidence The document is a letter from Biotron Limited's Company Secretary responding to a query from ASX Markets Supervision regarding a late filing of Appendix 3Y, which is a Change of Director's Interest Notice. The content focuses on compliance with listing rules related to director disclosures and the company's arrangements to ensure timely filings. There are no financial statements, earnings data, or report publications. The document is a regulatory communication about director share transactions and compliance with disclosure obligations. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 6143 characters, sufficient for a detailed letter but not a full financial report. Therefore, the correct classification is DIRS with high confidence.
2009-05-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.